PEA (Palmitoylethanolamide): Endogenous Lipid for Pain and Neuroinflammation
⚡ 60-Second Summary
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide found in cell membranes throughout the body, produced on demand in response to cellular stress and inflammation. It belongs to the same family as the endocannabinoids (anandamide, 2-AG) but is not itself a cannabinoid — it does not bind to CB1 or CB2 receptors significantly.
PEA's primary effects are mediated through PPAR-alpha (peroxisome proliferator-activated receptor alpha) activation, which downregulates mast cell degranulation and microglial activation — two key drivers of neuroinflammation and neuropathic pain. Research supports uses for neuropathic pain, fibromyalgia, osteoarthritis, chronic pain syndromes, and neuroinflammation.
PEA is not a painkiller in the conventional sense — it reduces neuroinflammation rather than directly blocking pain signals. Its effects build over weeks of consistent use. Ultramicronized (um-PEA) formulations have substantially better bioavailability than standard PEA and are used in most clinical trials.
What is PEA (Palmitoylethanolamide)?
PEA is produced throughout the body, including in the brain, spinal cord, and immune cells. FAAH (fatty acid amide hydrolase) breaks down PEA. When the body's inflammatory response is activated, PEA production increases locally as an endogenous counter-regulatory mechanism — supplementation extends and amplifies this response.
PEA was first isolated from egg yolk in 1957 and has been studied since the 1970s for its analgesic and anti-inflammatory properties. Modern interest accelerated with the discovery of PPAR-alpha as a receptor target and with development of ultramicronized formulations with improved bioavailability.
Evidence-based benefits
Neuropathic pain
Multiple RCTs and meta-analyses support um-PEA for sciatic pain, carpal tunnel syndrome, and diabetic neuropathy; effect sizes are clinically meaningful.
Fibromyalgia
Several RCTs show significant pain and symptom reduction with PEA supplementation in fibromyalgia; one of the better-studied supplement approaches for this condition.
Osteoarthritis and joint pain
Small RCTs report reduced pain and improved function; less evidence than for neuropathic pain.
Multiple sclerosis (neuroinflammation)
Pilot trials suggest PEA reduces pain and spasticity in MS; larger trials needed.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Ultramicronized PEA (um-PEA) | 600–1200 mg/day | Best absorbed; used in trials | Particle size <10 microns; substantially better bioavailability than standard PEA |
| Micronized PEA | 600–1200 mg/day | Good absorption | Intermediate particle size; similar to um-PEA in some studies |
| Standard PEA powder/capsules | 1200–2400 mg/day | Lower bioavailability | Larger particles; requires higher dose for equivalent effect |
How much should you take?
- 600 mg twice daily (1200 mg/day) of ultramicronized PEA in most clinical trials
- Effects typically build over 4–8 weeks; do not judge efficacy in less than 4 weeks
- Take with a fat-containing meal — PEA is a fatty acid and absorption is improved with dietary fat
PEA is remarkably well tolerated with an excellent safety profile across available trials. No significant serious adverse effects have been reported. Its endogenous nature suggests low inherent toxicity.
Safety and side effects
Common side effects
- Very well tolerated overall
- Mild GI effects at initiation in some users
- No significant hepatotoxicity or organ toxicity reported
Serious risks
PEA has minimal known drug interactions. It does not significantly affect CYP450 enzymes. Its analgesic effects may be additive with pain medications — this can be beneficial (allowing dose reduction of conventional analgesics) but should be monitored by a clinician.
Drug and nutrient interactions
- Analgesics / pain medications — additive effect possible; may allow dose reduction under medical supervision
- No established CYP450 interactions — PEA does not significantly inhibit or induce common drug-metabolizing enzymes
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| People with neuropathic pain (sciatica, diabetic neuropathy, carpal tunnel) | One of the better-evidenced supplements for neuropathic pain; use um-PEA formulation |
| People with fibromyalgia | Multiple RCTs support PEA for fibromyalgia pain and symptoms — discuss with clinician |
| People seeking analgesic dose reduction | PEA's additive effects may allow gradual conventional analgesic reduction; only under medical supervision |
| People with autoimmune or neurological disease on immunosuppressants | PEA's immune-modulating activity is mild and unlikely to interfere, but discuss with specialist |
Frequently asked questions
What is PEA and why is it called 'endogenous'?
PEA is a fatty acid amide produced naturally by your own cells in response to inflammation and cellular stress. Supplemental PEA amplifies this endogenous system. 'Endogenous' means produced inside the body.
Is PEA the same as CBD?
No. Both are naturally occurring anti-inflammatory lipids, but they are chemically distinct and work through different receptors. PEA primarily acts on PPAR-alpha; CBD works on multiple targets including CB2, TRPV1, and serotonin receptors. They may be synergistic.
Why does ultramicronized PEA matter?
Standard PEA powder has poor bioavailability because the large particles are poorly absorbed. Reducing particle size (micronization, ultramicronization) dramatically improves absorption. Most clinical trials demonstrating efficacy use micronized or ultramicronized PEA.
How long does PEA take to work?
Effects in clinical trials build over 4–8 weeks of consistent daily use. PEA is not a rapid-acting painkiller; it works by modulating the underlying neuroinflammatory process.
Can PEA be taken with conventional pain medications?
Yes — PEA has additive analgesic effects and has been studied alongside conventional treatments. The combination may allow dose reduction of conventional drugs, but do this under medical supervision.
Related ingredients
Boswellia
Anti-inflammatory botanical with overlapping joint and pain research
Curcumin
NF-κB anti-inflammatory with comparable pain evidence
Omega-3 (EPA/DHA)
Fatty acid anti-inflammatories with extensive pain research
CBD
Endocannabinoid-adjacent anti-inflammatory with neuropathic pain research
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.